Health
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…
Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…
Continue Reading
-
Business22 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
General19 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
Noosa News21 hours agoNew FLC President has regional lens – Proctor
-
Noosa News17 hours agoCCTV footage shows stolen ute slamming into fuel bowsers at Kojonup petrol station